27.42
-0.07 (-0.25%)
| Penutupan Terdahulu | 27.49 |
| Buka | 27.25 |
| Jumlah Dagangan | 1,204,903 |
| Purata Dagangan (3B) | 1,186,546 |
| Modal Pasaran | 1,598,964,736 |
| Harga / Jualan (P/S) | 34.99 |
| Harga / Buku (P/B) | 1.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | 1,798.26% |
| Margin Operasi (TTM) | -1,221.97% |
| EPS Cair (TTM) | 11.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.61% |
| Nisbah Semasa (MRQ) | 18.50 |
| Aliran Tunai Operasi (OCF TTM) | -401.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -237.66 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 60.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Agios Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.65% |
| % Dimiliki oleh Institusi | 101.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2025 | 5,781,066 |
| Erste Asset Management Gmbh | 30 Sep 2025 | 2,764,900 |
| Caligan Partners Lp | 30 Sep 2025 | 1,131,205 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (HC Wainwright & Co., 75.06%) | Beli |
| Median | 32.00 (16.70%) | |
| Rendah | 20.00 (JP Morgan, -27.06%) | Pegang |
| Purata | 32.13 (17.18%) | |
| Jumlah | 5 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 25.45 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 26 Nov 2025 | 38.00 (38.58%) | Beli | 29.04 |
| Truist Securities | 24 Nov 2025 | 32.00 (16.70%) | Beli | 26.49 |
| JP Morgan | 21 Nov 2025 | 20.00 (-27.06%) | Pegang | 25.24 |
| B of A Securities | 20 Nov 2025 | 32.00 (16.70%) | Beli | 24.57 |
| Goldman Sachs | 20 Nov 2025 | 25.00 (-8.83%) | Pegang | 24.57 |
| HC Wainwright & Co. | 20 Nov 2025 | 48.00 (75.05%) | Beli | 24.57 |
| Leerink Partners | 20 Nov 2025 | 34.00 (24.00%) | Beli | 24.57 |
| RBC Capital | 20 Nov 2025 | 28.00 (2.12%) | Pegang | 24.57 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2025 | Pengumuman | Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease |
| 03 Nov 2025 | Pengumuman | Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition |
| 30 Oct 2025 | Pengumuman | Agios Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 17 Oct 2025 | Pengumuman | Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia |
| 17 Oct 2025 | Pengumuman | Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia |
| 16 Oct 2025 | Pengumuman | Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |